Flibanserin (Addyi) is now the first FDA-approved drug for women distressed by low sexual desire, but the agent remains controversial. In this in-depth video analysis, F. Perry Wilson, MD, examines the data that drove the FDA's concerns and ultimate decision regarding the drug.
is an assistant professor of medicine at the Yale School of Medicine. He earned his BA from Harvard University, graduating with honors with a degree in biochemistry. He then attended Columbia College of Physicians and Surgeons in New York City. From there he moved to Philadelphia to complete his internal medicine residency and nephrology fellowship at the Hospital of the University of Pennsylvania. During his post graduate years, he also obtained a Master of Science in Clinical Epidemiology from the University of Pennsylvania. He is an accomplished author of many scientific articles and holds several NIH grants. He is a 51˶ reviewer, and in addition to his video analyses he authors a blog, You can follow.